A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3003-3011

  Bringmann, Gerhard ^a   Thomale, Katja ^a   Bischof, Sebastian ^a   Schneider, Christoph ^a   Schultheis, Martina ^a   Schwarz, Tobias ^a   Moll, Heidrun ^a   Schurigt, Uta ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; LUCIFERASE; LUCIFERIN; QUINOLINE DERIVATIVE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; DRUG SCREENING; DRUG SYNTHESIS; EVALUATION; FEMALE; IC 50; LEISHMANIA MAJOR; LUMINESCENCE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ORGANISM;

ANIMALS; ANTIPROTOZOAL AGENTS; AXENIC CULTURE; CELLS, CULTURED; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PARASITIC SENSITIVITY TESTS; QUINOLINIUM COMPOUNDS;

EID: 84879023366     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02201-12     Document Type: Article

References (43)

1. Ameen M. 2010. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin. Exp. Dermatol. 35:699-705.
2. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. 2009. Developments in the treatment of visceral leishmaniasis. Expert Opin. Emerg. Drugs 14:395-410.
3. Goto H, Lindoso JA. 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther. 8:419-433.
4. Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D. 2011. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol. Res. 109:1225-1232.
5. Choudhury K, Zander D, Kube M, Reinhardt R, Clos J. 2008. Identification of a Leishmania infantum gene mediating resistance to miltefosine and Sb III. Int. J. Parasitol. 38:1411-1423.
6. Srivastava P, Prajapati VK, Rai M, Sundar S. 2011. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J. Clin. Microbiol. 49:3088-3091.
7. Nagill R, Kaur S. 2011. Vaccine candidates for leishmaniasis: a review. Int. Immunopharmacol. 11:1464-1488.
8. Okwor I, Uzonna JE. 2009. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 1:765-776.
9. Fumarola L, Spinelli R, Brandonisio O. 2004. In vitro assays for evaluation of drug activity against Leishmania spp. Res. Microbiol. 155:224-230. (Pubitemid 38624168)
10. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, Jang J, Cechetto J, Lee CB, Moon S, Genovesio A, Chatelain E, Christophe T, Freitas-Junior LH. 2011. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl. Trop. Dis. 4:e675. doi:10.1371/journal.pntd. 0000675.
11. Patil V, Guerrant W, Chen PC, Gryder B, Benicewicz DB, Khan SI, Tekwani BL, Oyelere AK. 2010. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 18:415-425.
12. Ponte-Sucre A, Faber JH, Gulder T, Kajahn I, Pedersen SE, Schultheis M, Bringmann G, Moll H. 2007. Activities of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major. Antimicrob. Agents Chemother. 51:188-194. (Pubitemid 46047705)
13. Ponte-Sucre A, Vicik R, Schultheis M, Schirmeister T, Moll H. 2006. Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob. Agents Chemother. 50: 2439-2447. (Pubitemid 43993184)
14. Debrabant A, Joshi MB, Pimenta PF, Dwyer DM. 2004. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int. J. Parasitol. 34:205-217. (Pubitemid 38229824)
15. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grogl M, Magill AJ, Lazo JS. 2009. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl. Trop. Dis. 3:e540. doi:10.1371/journal.pntd.0000540.
16. Ponte-Sucre A, Gulder T, Wegehaupt A, Albert C, Rikanovic C, Schaeflein L, Frank A, Schultheis M, Unger M, Holzgrabe U, Bringmann G, Moll H. 2009. Structure-activity relationship and studies on the molecular mechanism of leishmanicidal N, C-coupled arylisoquinolinium salts. J. Med. Chem. 52:626-636.
17. Lang T, Goyard S, Lebastard M, Milon G. 2005. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell. Microbiol. 7:383-392. (Pubitemid 40277918)
18. Yang LK, Glover RP, Yoganathan K, Sarnaik JP, Godboleb AJ, Soejartoc DD, Bussa AD, Butler MS. 2003. Ancisheynine, a novel naphthylisoquinolinium alkaloid from Ancistrocladus heyneanus. Tetrahedron Lett. 44:5827-5829. (Pubitemid 36829219)
19. Bringmann G, Kajahn I, Reichert M, Pedersen SE, Faber JH, Gulder T, Brun R, Christensen SB, Ponte-Sucre A, Moll H, Heubl G, Mudogo V. 2006. Ancistrocladinium A and B, the first N, C-coupled naphthyldihydroisoquinoline alkaloids, from a Congolese Ancistrocladus species. J. Org. Chem. 71:9348-9356. (Pubitemid 44924516)
20. Bringmann G, Pokorny F. 1995. The naphthylisoquinoline alkaloids, p 127-271. In Cordell GA (ed), The alkaloids. Academic Press, New York, NY.
21. Bringmann G, Feineis G. 2000. Novel antiparasitic biaryl alkaloids from West African Dioncophyllaceae plants. Actual. Chim. Therapeut. 26:151-171.
22. Bringmann G, Gunther C, Ochse M, Schupp O, Tasler S. 2001. Biaryls in nature: a multi-facetted class of stereochemically, biosynthetically, and pharmacologically intriguing secondary metabolites. Fortschr. Chem. Org. Naturst. 82:1-249.
23. Bringmann G, Gulder T, Hertlein B, Hemberger Y, Meyer F. 2010. Total synthesis of the N, C-coupled naphthylisoquinoline alkaloids ancistrocladinium A and B and related analogues. J. Am. Chem. Soc. 132:1151-1158.
24. Bringmann G, Gulder T, Reichert M, Meyer F. 2006. Ancisheynine, the first N, C-coupled naphthylisoquinoline alkaloid: total synthesis and stereochemical analysis. Org. Lett. 8:1037-1040. (Pubitemid 43690654)
25. Bringmann G, Hertlein-Amslinger B, Kajahn I, Dreyer M, Brun R, Moll H, Stich A, Ioset KN, Schmitz W, Ngoc LH. 2011. Phenolic analogs of the N, C-coupled naphthylisoquinoline alkaloid ancistrocladinium A, from Ancistrocladus cochinchinensis (Ancistrocladaceae), with improved antiprotozoal activities. Phytochemistry 72:89-93.
26. Ponte-Sucre A, Gulder T, Gulder TA, Vollmers G, Bringmann G, Moll H. 2010. Alterations to the structure of Leishmania major induced by N-arylisoquinolines correlate with compound accumulation and disposition. J. Med. Microbiol. 59:69-75.
27. Dimroth K, Odenwaelder H. 1971. Reaktionen mit Benzound Naphthopyryliumsalzen. Chem. Ber. 104:2984-2994.
28. Reimann E. 1991. 1-Alkyl-und 1-Aryl-chinolinium-Salze. Methoden Org. Chem. (Houben-Weyl) E 7a:542-570.
29. Schleicher U, Bogdan C. 2009. Generation, culture and flow-cytometric characterization of primary mouse macrophages. Methods Mol. Biol. 531: 203-224.
30. Schurigt U, Schad C, Glowa C, Baum U, Thomale K, Schnitzer JK, Schultheis M, Schaschke N, Schirmeister T, Moll H. 2010. Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagyrelated lysosome-like vacuoles. Antimicrob. Agents Chemother. 54:5028-5041.
31. Huber W, Koella JC. 1993. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 55:257-261.
32. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. (Pubitemid 29278954)
33. Liebsch M, Grune B, Seiler A, Butzke D, Oelgeschlager M, Pirow R, Adler S, Riebeling C, Luch A. 2011. Alternatives to animal testing: current status and future perspectives. Arch. Toxicol. 85:841-858.
34. Russel WMS, Burch RL. 1959. The principles of human experimental technique. Methuen & Co Ltd, London, United Kingdom.
35. Schmid H, Sauerbrei R, Schwarz G, Weber E, Kalbacher H, Driessen C. 2002. Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages. Biol. Chem. 383: 1277-1283. (Pubitemid 35215078)
36. Nwaka S, Hudson A. 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5:941-955. (Pubitemid 44660607)
37. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. 2009. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl. Trop. Dis. 3:e440. doi:10.1371/journal.pntd.0000440.
38. Channon JY, Roberts MB, Blackwell JM. 1984. A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages. Immunology 53:345-355. (Pubitemid 14002300)
39. de Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH. 2011. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl. Trop. Dis. 5:e1253. doi:10.1371/journal.pntd.0001253.
40. Mandal S, Maharjan M, Ganguly S, Chatterjee M, Singh S, Buckner FS, Madhubala R. 2009. High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric betalactamase assay. Indian J. Exp. Biol. 47:475-479.
41. Plock A, Sokolowska-Kohler W, Presber W. 2001. Application of flow cytometry and microscopical methods to characterize the effect of herbal drugs on Leishmania spp. Exp. Parasitol. 97:141-153. (Pubitemid 32980596)
42. Siqueira-Neto JL, Moon S, Jang J, Yang G, Lee C, Moon HK, Chatelain E, Genovesio A, Cechetto J, Freitas-Junior LH. 2012. An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl. Trop. Dis. 6:e1671. doi:10.1371/journal.pntd.0001671.
43. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53:3855-3859.